Gyre Therapeutics (GYRE) announced that its indirect, majority-owned subsidiary, Gyre Pharmaceuticals has completed patient enrollment in the 52-week Phase 3 clinical trial of its Class 1 drug, Pirfenidone capsules, for the treatment of pneumoconiosis. A total of 272 patients have been enrolled in this multicenter, randomized, double-blind, placebo-controlled trial being conducted at 18 clinical research centers across China. The trial is designed to evaluate the efficacy and safety of 52 weeks of Pirfenidone capsule treatment in patients with pneumoconiosis, a chronic occupational lung disease characterized by progressive pulmonary fibrosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Gyre Therapeutics initiated with a Buy at Jefferies
- Gyre Therapeutics Announces Positive Phase 3 Results
- Gyre Therapeutics: A Compelling Buy with Potential Blockbuster Drug Hydronidone Targeting Liver Fibrosis
- Gyre Therapeutics initiated with a Buy at H.C. Wainwright
- Gyre Therapeutics Appoints Dan Weng to Board